Avillion LLP

5:00 PM - 5:15 PM, Monday, June 3, 2019 ・ Theater 4
Accelerating global drug development through successful partnering for patient benefit. Our objective is to enable our partners to continue to develop their most important drug candidates without increasing the burden on their P&L or cash reserves.
Ticker:
Not Provided.
Exchange:
Not Provided.
Company Type:
Company Website:
Company HQ State:
Not Provided.
Company HQ Country:
United Kingdom
Year Founded:
2012
Main Therapeutic Focus:
Lead Product in Development:
PT027 an investigational fixed dose combination of budesonide & albuterol for treatment of asthma
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.
Speaker
photo
CEO
Avillion LLP